AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Living Cell Technologies Limited (ASX:LCT) has presented the trial results from the Phase IIb study of NTCELL for Parkinson's disease. The trial commenced in March month of year 2016. The lead product of LCT, which is NTCELL is a capsule coated with alginate and has neonatal porcine choroid plexus cells based clusters.
NTCELL when it gets planted, works as a biological factory that induces factors to promote the development of new growth of the central nervous system and repair disease due to nerve degeneration. NTCELL has significant potential and finds utility in a diverse set of central nervous system indications. These include Alzheimerâs and motor neuron diseases such as amyotrophic lateral sclerosis.
The company has presented this data with the study conducted on 18 patients with the 18 months follow in the phase IIb study of NTCELL. The study was done in order to confirm about the most effective dose of NTCELL and to define the response of any placebo component. The study also finds support in cases wherein identification of initial target Parkinsonâs disease becomes crucial.
Three groups were made with each group consisting of six patients during the study. Two patients from each group undergone sham surgery with no implantation of the NTCELL to act as a control. 40 microcapsules of NTCELL implanted on each side of the brain were received by the group 1, 80 microcapsules of NTCELL received by the group 2 and 120 microcapsules of NTCELL received by the group 3.
Unified Parkinsonâs disease rating scale consisting of four sub-scales, one of which is motor examination is used to measure the efficacy. All the measurements are recorded when patients are off symptomatic treatments.
Statistically significant improvement with p<=0.05 as measured through unified Parkinson's disease rating scale in the patients who were implanted with 80 NTCELL capsules to the putamen on both sides of the brain was noted as compared to the placebo group who had sham surgery during the initial analysis of the 18-month data. However, no such benefit was noted from the group 3 who have received 120 microcapsules on NTCELL capsules. Evidence of inflammation was noted which may have compromised efficacy in this group.
Dr Barry Snow from Auckland City Hospital, the principal Investigator for the Phase IIb study of NTCELL for Parkinson's disease stated that statistically significant improvements were noticed for 12 months and have remained at sustained levels with slight variation between the recipients on small number of subjects.
The next step in this direction is further in-depth analysis to completely understand the data on all efficacy measurements both on and off normal symptomatic treatment. The company will have a clear picture and will be able to confirm on its ongoing strategy for NTCELL once an in-depth analysis of the data along with appropriate discussions with the concerned regulatory authorities at New Zealand are done.
LCT with its previous day close at $0.051 to an intraday high of $0.075, has initially recorded approximately 47% upside in today's session and is currently trading at the levels of $0.056 (up 9.8% on November 02, 2018, 3:45 PM AEST).
Disclaimer
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkinemedia.com and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.
